About us

ABOUT US

XING Technologies is an Australian-based biotechnology company specialising in transformative diagnosis and monitoring technologies for cancer and disease.

The company’s proprietary nanotechnologies are transforming the future practice of medicine and enabling personalised healthcare. XING’s service and product lines currently span from cancer care to rapid nucleic acid extraction, protein detection diagnostics and nanoparticle capture agents to identify and prevent the spread of infectious diseases.

“The dedicated team of scientists is solely focused on improving the quality of life of patients affected by cancer" –

Paul Mainwaring – Co-Founder, CEO & Chairman

Dr Paul Mainwaring

Co-Founder & Executive Chairman & CEO

Yadveer S. Grewal, PhD
Product Manager
Dr Lynn Fink
Clinical Bioinformatician
Rebecca Perkins
Quality Manager
Kevin Koo
Development & Laboratory Director
Scroll to Top

Dr Paul Mainwaring

Co-Founder & Executive Chairman

Paul worked as a medical oncologist for 25 years, with an emphasis on basic, clinical and translational research applying new technologies to deliver the best available personalised care to patients and their carers. He published extensively in the world’s leading cancer journals including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology amongst others.

After Paul’s initial Medical Oncology training in Sydney at Royal Prince Alfred and Royal North Shore hospitals he moved to the Royal Marsden in London – Europe’s largest cancer hospital. Paul completed his MD in cell death at the Institute of Cancer Research and was appointed as a consultant at Guy’s, King’s and St Thomas’ NHS Trusts in 1999.

In 2002, Paul returned to Australia as Director of Medical Oncology, Mater Adult Hospital and in 2008 Paul transferred across into private practice in Queensland continuing his translational & clinical research. As part of this work he came across the disruptive nanotechnologies being developed in Queensland that could transform patient care.

In 2019, Paul transitioned across from working as a medical oncologist to XING to assist the brilliant team of researchers in bringing the XING vision to patients.

Yadveer S. Grewal, PhD

Product Manager

Yadveer leads the Protein Chemistry development team and with the team, drives the advancement of the XavTrap® platform and serves as the Product Manager. Prior to joining XING, Yadveer co-invented the XavTrap® technology during his PhD in Nanobiotechnology at The University of Queensland. Yadveer has been awarded $1.25M USD in grant funding from the US National Institutes of Health RADx program to commercialise the XavTrap® platform.

Dr Lynn Fink

Clinical Bioinformatician

Following a successful academic career in computational cancer genomics research, Lynn made the leap to industry in order to focus on using novel and disruptive technologies to address unmet clinical needs.

She joined XING Genomic Services team as Laboratory Director of our NATA-accredited ISO15189 human pathology lab but now focuses on clinical bioinformatics and novel assay development.

Lynn has been involved in large, international research consortia including the International Cancer Genome Consortium (ICGC), which has resulted in a major resource of almost 3,000 whole cancer genomes, underpinning most cancer genome research projects.

To date, Lynn has over 80 publications in molecular biology and bioinformatics many of which are in high-impact journals such as Nature, Nature Methods, Nature Genetics, Nature Communications, PNAS, PLoS Genetics, Genome Research, and Genome Biology. 

Rebecca Perkins

Quality Manager

Rebecca is a passionate, customer focussed quality professional having worked in senior management and executive positions in quality improvement and management across healthcare including pathology, research, health, aged, disability and community care in Australia and abroad. 

Rebecca has a clinical background in Physiotherapy, a Masters in Public Health and Health Management (UNSW), and further training in Six Sigma Green Belt, Lead Quality Improvement (Australian Council on Healthcare Standards), Patient Safety Specialisation (Johns Hopkins University) and has Fellowship training from the International Society for Quality and Safety in Healthcare.

Rebecca has a strong background in health care accreditation and regulatory settings having led, designed, developed, implemented, maintained, evaluated and improved quality management systems across multiple standards including ISO 15189, ISO 9001 and the NDIS Quality practice standards. 

She has proven abilities to effectively lead and implement change in complex environments, has driven quality improvement initiatives, including in the NHS, utilising clinical practice improvement methodologies. Rebecca also possesses key skills in risk management, training and evaluation, data collection and analysis, project management, business development and human resources.

Kevin Koo

Development & Laboratory Director

Kevin oversees assay project management and laboratory operations in his roles as the Head of Assay Development and Laboratory Director. His focus encompasses the multidisciplinary fields of developing and commercializing molecular assay and biosensor products for precision disease management applications.

Prior to joining XING full time in 2018, he completed his doctoral research on nanobiosensors for non-invasive prostate cancer biomarkers, which was recognized by multiple national/global research awards.

Kevin holds a Ph.D. in cancer nanobtiotechnology from the Australian Institute for Bioengineering & Nanotechnology at The University of Queensland (UQ) and is an appointed Honorary Fellow of UQ Centre for Clinical Research. Outside of XING, he enjoys doing and training for endurance sports.